147 related articles for article (PubMed ID: 18158122)
1. Dyslipidemia can reduce the immunosuppressive effects of cyclosporine.
Pozzetto U; Citterio F; Fioravanti G; Navarra P; Boccalini F; Castagneto M
Transpl Immunol; 2008 Feb; 18(4):349-51. PubMed ID: 18158122
[TBL] [Abstract][Full Text] [Related]
2. Activation of PPARgamma enhances in vitro the immunosuppressive effect of cyclosporine on T lymphocytes.
Rampino T; Ranghino A; Guidetti C; Gregorini M; Soccio G; Marasà M; Libetta C; Guida G; De Amici M; Dal Canton A
Transpl Immunol; 2007 Jul; 18(1):32-6. PubMed ID: 17584600
[TBL] [Abstract][Full Text] [Related]
3. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients.
Falck P; Asberg A; Guldseth H; Bremer S; Akhlaghi F; Reubsaet JL; Pfeffer P; Hartmann A; Midtvedt K
Transplantation; 2008 Jan; 85(2):179-84. PubMed ID: 18212621
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the sensitivity of pig and human peripheral blood mononuclear cells to the antiproliferative effects of traditional and newer immunosuppressive agents.
Wright DC; Deol HS; Tuch BE
Transpl Immunol; 1999 Sep; 7(3):141-7. PubMed ID: 10608297
[TBL] [Abstract][Full Text] [Related]
5. Strong additive effect of calcitriol and cyclosporine A on lymphocyte proliferation in vitro and rat liver allotransplantations in vivo.
Zhang AB; Zheng SS
Chin Med J (Engl); 2006 Dec; 119(24):2090-5. PubMed ID: 17199961
[TBL] [Abstract][Full Text] [Related]
6. Suppression of acute and chronic cardiac allograft rejection in mice by inhibition of chemokine receptor 5 in combination with cyclosporine A.
Li J; Xia J; Zhang K; Xu L
J Surg Res; 2009 Nov; 157(1):81-90. PubMed ID: 19577762
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the immunosuppressive effects of cyclosporine A and cyclosporine G in vivo and in vitro.
Rayat G; Yatscoff R; Silverman R; McKenna R
Transplantation; 1993 Mar; 55(3):623-6. PubMed ID: 8456482
[TBL] [Abstract][Full Text] [Related]
8. Human allograft arterial injury is ameliorated by sirolimus and cyclosporine and correlates with suppression of interferon-gamma.
Yi T; Cuchara L; Wang Y; Koh KP; Ranjbaran H; Tellides G; Pober JS; Lorber MI
Transplantation; 2006 Feb; 81(4):559-66. PubMed ID: 16495804
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of the effects of betamethasone butyrate propionate, vitamin D3 derivatives, and cyclosporine on human lymphocyte-proliferation stimulated with a hemolytic streptococci-derived superantigen.
Arai K; Uchiyama T; Okubo Y; Tsuboi R; Oka K; Hirano T
Eur J Pharmacol; 2007 Oct; 571(2-3):222-30. PubMed ID: 17628528
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine monitoring in peripheral blood mononuclear cells: feasibility and interest. A prospective study on 20 renal transplant recipients.
Lepage JM; Lelong-Boulouard V; Lecouf A; Debruyne D; Hurault de Ligny B; Coquerel A
Transplant Proc; 2007 Dec; 39(10):3109-10. PubMed ID: 18089333
[TBL] [Abstract][Full Text] [Related]
11. Intrarenal activation of renin angiotensin system in the development of cyclosporine A induced chronic nephrotoxicity.
Shang MH; Yuan WJ; Zhang SJ; Fan Y; Zhang Z
Chin Med J (Engl); 2008 Jun; 121(11):983-8. PubMed ID: 18706245
[TBL] [Abstract][Full Text] [Related]
12. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
Roos M; Liu S; Strobl M; Schmaderer C; Baumann M; Heemann U; Lutz J
Transplant Proc; 2008 Dec; 40(10):3731-6. PubMed ID: 19100477
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine A inhibits lymphocyte migration into ovine peripheral nerve allografts.
Hare GM; Mackinnon SE; Midha R; Wong PY; Au B; Munro C; Andrade W; Hunter DA; Hay JB
Microsurgery; 1996; 17(12):697-705. PubMed ID: 9588715
[TBL] [Abstract][Full Text] [Related]
15. FK778 ameliorates post-transplant expression of fibrogenic growth factors and development of chronic rejection changes in rat kidney allografts.
Rintala JM; Savikko J; Rintala SE; von Willebrand E
Nephrol Dial Transplant; 2008 Nov; 23(11):3446-55. PubMed ID: 18558624
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
[TBL] [Abstract][Full Text] [Related]
17. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
Troncoso P; Ortiz AM; Jara A; Vilches S
Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase C inhibitor, AEB-071, acts complementarily with cyclosporine to prevent islet rejection in rats.
Merani S; Pawlick RL; Edgar RL; Toso C; Emamaullee J; Anderson CC; Shapiro AM
Transplantation; 2009 Jan; 87(1):59-65. PubMed ID: 19136892
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level.
Calvo-Turrubiartes M; Romano-Moreno S; García-Hernández M; Chevaile-Ramos JA; Layseca-Espinosa E; González-Amaro R; Portales-Pérez D
Transpl Immunol; 2009 May; 21(1):43-9. PubMed ID: 19233271
[TBL] [Abstract][Full Text] [Related]
20. Modulation by immunosuppressive agents of peripheral blood mononuclear cell responses to influenza A virus.
Gorse GJ; Kopp WC
J Lab Clin Med; 1987 Nov; 110(5):592-601. PubMed ID: 2444663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
